{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:44:42Z","timestamp":1793378682507,"version":"4.5.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.eclinm.2024.102446","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T17:37:36Z","timestamp":1708018656000},"page":"102446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["The RELIVE consortium for relapsed or refractory pediatric hepatoblastoma and hepatocellular carcinoma: a scoping review of the problem and a proposed solution"],"prefix":"10.1016","volume":"69","author":[{"given":"Allison F.","family":"O\u2019Neill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Trobaugh-Lotrario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James I.","family":"Geller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiso","family":"Hiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brice","family":"Fresneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Toutain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard M.","family":"Katzenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Morland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Branchereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6716-4347","authenticated-orcid":false,"given":"J\u00f3zsef","family":"Zsiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Maibach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2024.102446_bib1","series-title":"SEER cancer statistics review, 1975-2009","year":"2009"},{"key":"10.1016\/j.eclinm.2024.102446_bib2","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkz007","article-title":"Trends in international incidence of pediatric cancers in children under 5 years of age: 1988-2012","volume":"3","author":"Hubbard","year":"2019","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.eclinm.2024.102446_bib3","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.3748\/wjg.v24.i35.3980","article-title":"Pediatric hepatocellular carcinoma","volume":"24","author":"Khanna","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.eclinm.2024.102446_bib4","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ejca.2012.10.003","article-title":"Relapses in hepatoblastoma patients: clinical characteristics and outcome--experience of the International Childhood Liver Tumour Strategy Group (SIOPEL)","volume":"49","author":"Semeraro","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eclinm.2024.102446_bib5","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1002\/cncr.30591","article-title":"Upfront window vincristine\/irinotecan treatment of high-risk hepatoblastoma: a report from the Children\u2019s Oncology Group AHEP0731 study committee","volume":"123","author":"Katzenstein","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.eclinm.2024.102446_bib6","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1200\/JCO.19.01067","article-title":"Outcome and late complications of hepatoblastomas treated using the Japanese Study Group for pediatric liver tumor 2 protocol","volume":"38","author":"Hiyama","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102446_bib7","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1470-2045(13)70272-9","article-title":"Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study","volume":"14","author":"Zsiros","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2024.102446_bib8","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1470-2045(18)30895-7","article-title":"Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children\u2019s Oncology Group, multicentre, phase 3 trial","volume":"20","author":"Katzenstein","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102446_bib9","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/cncr.34014","article-title":"Doxorubicin in combination with cisplatin, 5-flourouracil, and vincristine is feasible and effective in unresectable hepatoblastoma: a Children\u2019s Oncology Group study","volume":"128","author":"Katzenstein","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.eclinm.2024.102446_bib10","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.2002.06.102","article-title":"Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group","volume":"20","author":"Czauderna","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102446_bib11","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.2002.06.155","article-title":"Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children\u2019s Cancer Group intergroup study","volume":"20","author":"Katzenstein","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102446_bib12","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/pbc.24218","article-title":"Relapsed hepatoblastoma","volume":"59","author":"Trobaugh-Lotrario","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.eclinm.2024.102446_bib13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/MPH.0000000000000474","article-title":"Outcomes of patients with relapsed hepatoblastoma enrolled on Children's Oncology Group (COG) phase I and II studies","volume":"38","author":"Trobaugh-Lotrario","year":"2016","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.eclinm.2024.102446_bib14","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1200\/JCO.2006.09.7204","article-title":"Redefining the role of doxorubicin for the treatment of children with hepatoblastoma","volume":"26","author":"Malogolowkin","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102446_bib15","first-page":"32","article-title":"A phase I study of irinotecan in pediatric patients: a pediatric oncology group study","volume":"7","author":"Blaney","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eclinm.2024.102446_bib16","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1097\/00043426-200212000-00014","article-title":"Novel therapeutic approaches in the treatment of children with hepatoblastoma","volume":"24","author":"Katzenstein","year":"2002","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.eclinm.2024.102446_bib17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/mpo.10300","article-title":"Dramatic response of multiply relapsed hepatoblastoma to irinotecan (CPT-11)","volume":"41","author":"Palmer","year":"2003","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.eclinm.2024.102446_bib18","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2003.08.175","article-title":"A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors","volume":"21","author":"Vassal","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102446_bib19","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1399-3046.2006.00517.x","article-title":"Response of heavily treated and relapsed hepatoblastoma in the transplanted liver to single-agent therapy with irinotecan","volume":"10","author":"Ijichi","year":"2006","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.eclinm.2024.102446_bib20","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1200\/JCO.2007.11.6103","article-title":"Phase II trial of irinotecan in children with refractory solid tumors: a Children\u2019s Oncology Group Study","volume":"25","author":"Bomgaars","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102446_bib21","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/pbc.22460","article-title":"Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors","volume":"54","author":"McNall-Knapp","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.eclinm.2024.102446_bib22","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/pbc.22408","article-title":"Irinotecan as maintenance therapy in high-risk hepatoblastoma","volume":"54","author":"Qayed","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.eclinm.2024.102446_bib23","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/pbc.22407","article-title":"Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children\u2019s Oncology Group phase I consortium study","volume":"54","author":"Wagner","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.eclinm.2024.102446_bib24","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1016\/j.ejca.2012.06.023","article-title":"Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma--a phase II trial of the childhood liver tumour strategy group (SIOPEL)","volume":"48","author":"Zsiros","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eclinm.2024.102446_bib25","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/pbc.24874","article-title":"Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children\u2019s Oncology Group Study","volume":"61","author":"Bagatell","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.eclinm.2024.102446_bib26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3109\/08880018.2014.909913","article-title":"Vincristine and irinotecan in children with relapsed hepatoblastoma: a single-institution experience","volume":"32","author":"Zhang","year":"2015","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.eclinm.2024.102446_bib27","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1097\/MPH.0000000000001171","article-title":"Addition of vincristine and irinotecan to standard therapy in a patient with refractory high-risk hepatoblastoma achieving long-term relapse-free survival","volume":"41","author":"Powers","year":"2019","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.eclinm.2024.102446_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28655","article-title":"Pilot study of the combination of sorafenib and fractionated irinotecan in pediatric relapse\/refractory hepatic cancer (FINEX pilot study)","volume":"67","author":"Keino","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.eclinm.2024.102446_bib29","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/mpo.2950210711","article-title":"Cisplatin-resistant metastatic hepatoblastoma: complete response to carboplatin, etoposide, and liver transplantation","volume":"21","author":"Lockwood","year":"1993","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.eclinm.2024.102446_bib30","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1002\/1097-0142(19950615)75:12<2966::AID-CNCR2820751226>3.0.CO;2-W","article-title":"Etoposide, ifosfamide, and cisplatin therapy for refractory childhood solid tumors. Response and toxicity","volume":"75","author":"van Hoff","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.eclinm.2024.102446_bib31","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1055\/s-2008-1043805","article-title":"Analysis of treatment efficiency of carboplatin and etoposide in combination with radical surgery in advanced and recurrent childhood hepatoblastoma: a report of the German Cooperative Pediatric Liver Tumor Study HB 89 and HB 94","volume":"211","author":"Fuchs","year":"1999","journal-title":"Klin Padiatr"},{"key":"10.1016\/j.eclinm.2024.102446_bib32","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s00383-002-0906-0","article-title":"Analysis of treatment outcome for children with recurrent or metastatic hepatoblastoma","volume":"19","author":"Matsunaga","year":"2003","journal-title":"Pediatr Surg Int"},{"key":"10.1016\/j.eclinm.2024.102446_bib33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/pbc.10375","article-title":"Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide\/carboplatin\/etoposide (ICE): a phase II study in a pediatric oncology centre in Brazil","volume":"42","author":"Loss","year":"2004","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.eclinm.2024.102446_bib34","doi-asserted-by":"crossref","first-page":"E87","DOI":"10.1111\/j.1399-3046.2009.01262.x","article-title":"Successful treatment of unresectable advanced hepatoblastoma: living liver transplantation after surgical removal of lung metastasis","volume":"15","author":"Miyamura","year":"2011","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.eclinm.2024.102446_bib35","doi-asserted-by":"crossref","first-page":"e659","DOI":"10.1097\/MPH.0000000000001544","article-title":"Sustained remission after maintenance irinotecan in patient with multiply relapsed hepatoblastoma","volume":"42","author":"Natarajan","year":"2020","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.eclinm.2024.102446_bib36","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.pedneo.2021.03.018","article-title":"A\u00a0retrospective study of clinical features and outcome in patients with refractory or recurrent hepatoblastoma: a single institution experience","volume":"62","author":"Hou","year":"2021","journal-title":"Pediatr Neonatol"},{"key":"10.1016\/j.eclinm.2024.102446_bib37","article-title":"Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors","volume":"7","author":"Tsuchiya","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.eclinm.2024.102446_bib38","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/sj.bmt.1701283","article-title":"Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors","volume":"22","author":"Hara","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.eclinm.2024.102446_bib39","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/MPH.0000000000000554","article-title":"Cerebral metastasis of hepatoblastoma: a review","volume":"38","author":"Rai","year":"2016","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.eclinm.2024.102446_bib40","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jpedsurg.2015.10.053","article-title":"Relapsed hepatoblastoma confined to the lung is effectively treated with pulmonary metastasectomy","volume":"51","author":"Shi","year":"2016","journal-title":"J Pediatr Surg"},{"key":"10.1016\/j.eclinm.2024.102446_bib41","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1056\/NEJMoa0810613","article-title":"Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma","volume":"361","author":"Perilongo","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2024.102446_bib42","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1200\/JCO.2009.22.4857","article-title":"Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study","volume":"28","author":"Zsiros","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102446_bib43","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/cncr.10632","article-title":"Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94","volume":"95","author":"Fuchs","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.eclinm.2024.102446_bib44","series-title":"Pediatric liver tumors","author":"Zsiros","year":"2011"},{"key":"10.1016\/j.eclinm.2024.102446_bib45","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/pbc.22544","article-title":"A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children\u2019s Oncology Group study","volume":"55","author":"Beaty","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.eclinm.2024.102446_bib46","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/pbc.24605","article-title":"Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children\u2019s Oncology Group","volume":"61","author":"Weigel","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.eclinm.2024.102446_bib47","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.ejca.2004.01.042","article-title":"Phase II study of high-dose cyclophosphamide in relapsing and\/or resistant hepatoblastoma in children: a study from the SIOPEL group","volume":"40","author":"Cacciavillano","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eclinm.2024.102446_bib48","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1158\/1078-0432.CCR-11-3251","article-title":"Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children\u2019s Oncology Group Phase I Consortium study","volume":"18","author":"Mosse","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eclinm.2024.102446_bib49","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1200\/JCO.2012.47.0914","article-title":"Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a Children\u2019s Oncology Group phase I consortium report","volume":"31","author":"Glade Bender","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102446_bib50","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1046\/j.1442-200X.2002.01549.x","article-title":"High-dose chemotherapy in children with metastatic hepatoblastoma","volume":"44","author":"Nishimura","year":"2002","journal-title":"Pediatr Int"},{"key":"10.1016\/j.eclinm.2024.102446_bib51","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/pbc.20404","article-title":"Allogeneic graft-versus-hepatoblastoma effect","volume":"46","author":"Inaba","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.eclinm.2024.102446_bib52","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1399-3046.2008.00948.x","article-title":"Successful autologous peripheral blood stem cell transplantation with a double-conditioning regimen for recurrent hepatoblastoma after liver transplantation","volume":"13","author":"Niwa","year":"2009","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.eclinm.2024.102446_bib53","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/MPH.0000000000000130","article-title":"Treatment of hepatoblastoma with high-dose chemotherapy and stem cell rescue: the pediatric blood and marrow transplant consortium experience and review of the literature","volume":"36","author":"Karski","year":"2014","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.eclinm.2024.102446_bib54","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/0360-3016(92)90007-5","article-title":"Is there a place for radiation therapy in the management of hepatoblastomas and hepatocellular carcinomas in children?","volume":"23","author":"Habrand","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eclinm.2024.102446_bib55","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/pbc.20422","article-title":"Preliminary experience with arterial chemoembolization for hepatoblastoma and hepatocellular carcinoma in children","volume":"46","author":"Czauderna","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.eclinm.2024.102446_bib56","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27510","article-title":"Transarterial radioembolization with yttrium-90 of unresectable primary hepatic malignancy in children","volume":"66","author":"Aguado","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.eclinm.2024.102446_bib57","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1007\/s00261-019-02011-5","article-title":"Microwave ablation assisted by three-dimensional visualization system as local therapy for relapsed hepatoblastoma: a small pilot study","volume":"44","author":"Cui","year":"2019","journal-title":"Abdom Radiol"},{"key":"10.1016\/j.eclinm.2024.102446_bib58","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000012607","article-title":"Microwave ablation combined with transcatheter arterial chemoembolization is effective for treating unresectable hepatoblastoma in infants and children","volume":"97","author":"Jiang","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.eclinm.2024.102446_bib59","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/pbc.10376","article-title":"Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience","volume":"42","author":"Otte","year":"2004","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.eclinm.2024.102446_bib60","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1055\/s-0038-1668148","article-title":"Prognostic factors for liver transplantation in unresectable hepatoblastoma","volume":"29","author":"Triana Junco","year":"2019","journal-title":"Eur J Pediatr Surg"},{"key":"10.1016\/j.eclinm.2024.102446_bib61","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27475","article-title":"Is hepatocellular carcinoma the same disease in children and adults? Comparison of histology, molecular background, and treatment in pediatric and adult patients","volume":"66","author":"Weeda","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102446_bib62","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/hep.28888","article-title":"Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups","volume":"65","author":"Sumazin","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.eclinm.2024.102446_bib63","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1038\/s41467-021-25430-9","article-title":"Genetic and epigenetic basis of hepatoblastoma diversity","volume":"12","author":"Nagae","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.eclinm.2024.102446_bib64","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s00247-014-3000-6","article-title":"Relapse surveillance in AFP-positive hepatoblastoma: re-evaluating the role of imaging","volume":"44","author":"Rojas","year":"2014","journal-title":"Pediatr Radiol"},{"key":"10.1016\/j.eclinm.2024.102446_bib65","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/modpathol.2013.80","article-title":"Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium","volume":"27","author":"Lopez-Terrada","year":"2014","journal-title":"Mod Pathol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024000257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024000257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:36:06Z","timestamp":1781642166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024000257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":65,"alternative-id":["S2589537024000257"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102446","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The RELIVE consortium for relapsed or refractory pediatric hepatoblastoma and hepatocellular carcinoma: a scoping review of the problem and a proposed solution","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102446","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102446"}}